Clinical trials: Genome
Single-Gene Disease
Analysis of Human Genomic DNA in Embryo's Culture Media
try to find genomic DNA in culture medium after the embryos develop on Day 3 and Day 5 also in single step culture media. using direct PCR Polymerase Chain Reaction and also WGA Whole Genome Amplification before PCR and…
- Trial name
- NCT02359747
- Testing
- Polymerase Chain Reaction and Whole Genome Amplification
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Cervesi Hospital, Cattolica, Italy
Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma
Gene Expression in Patients With Metastatic Prostate Cancer Receiving CYP-17 Inhibition Therapy
This research trial studies gene expression in patients with prostate cancer that has spread to other places in the body receiving cytochrome P450 17 alpha hydroxylase/17,20 lyase (CYP-17) inhibition therapy.
- Conditions
- Hormone-Resistant Prostate Cancer, Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Recurrent Prostate Carcinoma
- Trial name
- PROMOTE (NCT01953640)
- Testing
- Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- 3 sites in United States
- Volunteers
- 92 people
- Sponsor
- Mayo Clinic
Parkinson's Disease
Combined Genome and RNA Sequencing for Genetic Diagnosis of Parkinsonism
Despite the increasing availability and advances in the analysis of high-throughput DNA sequencing, the majority of patients with early-onset or familial parkinsonism remain without a molecular diagnosis.
- Trial name
- ParkOmic (NCT06576713)
- Testing
- Combiner whole genome and RNA sequencing
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Strasbourg, France
Pediatric Solid Tumor
The iCat2, GAIN (Genomic Assessment Informs Novel Therapy) Consortium Study
This research study is evaluating the use of specialized testing of solid tumors including sequencing. The process of performing these specialized tests is called tumor profiling.
- Trial name
- NCT02520713
- Testing
- Genetic testing and GAIN report
- Where
- 12 sites in United States
- Volunteers
- 825 people
- Sponsor
- Dana-Farber Cancer Institute
Cancer Childhood
Ultrafast Whole Genome Sequencing for Childhood Cancer
Cambridge University Hospitals NHS Foundation Trust (CUHNFT) is the Principal Treatment Centre for the East of England region, responsible for 120-150 patients <16 years with a new diagnosis of paediatric malignancy annually;…
- Trial name
- UF-WGS (NCT07201038)
- Where
- United Kingdom
- Volunteers
- 50 people
- Sponsor
- University of Cambridge
mCRPC, Male Urogenital Diseases
The Radium-select Study
Radium-223 is an established radionuclide therapy for patients with metastatic castration resistant prostate cancer (mCRPC) and symptomatic bone metastasis.
- Trial name
- NCT06659926
- Testing
- 68Ga-PSMA-PET/CT scan
- Where
- 5 sites in Netherlands
- Volunteers
- 60 people
- Sponsor
- The Netherlands Cancer Institute
Developmental Anomalies
Study of the Diagnostic Value of "Rapid" High Throughput Genome Sequencing Analysis in Diagnostic Emergency Situations
Rare diseases (affecting less than one in 2,000 people) are a major public health issue. There are about 8,000 rare diseases and they affect more than 3 million people in France.
- Trial name
- FASTGEN (NCT03956069)
- Testing
- blood sample, genome sequencing
- Where
- France
- Volunteers
- 57 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Colorectal Neuroendocrine Carcinomas (CRNEC); Genomic Landscape; Genetic Landscape; Prognosis; CCL5; PAX5
Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine Carcinoma
Background: Colorectal neuroendocrine carcinomas (CRNECs) are highly aggressive tumours with poor prognosis and low incidence. To date, the genomic landscape and molecular pathway alterations have not been elucidated.
- Trial name
- NCT05714722
- Volunteers
- 60 people
- Sponsor
- Zhejiang University
Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Functional precision medicine (FPM) is a relatively new approach to cancer therapy based on direct exposure of patient- isolated tumor cells to clinically approved drugs and integrates ex vivo drug sensitivity testing (DST) and…
- Conditions
- Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Large Cell Lymphoma, Refractory Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT05857969
- Testing
- Functional Precision Medicine
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- Florida International University
Haematological Malignancy, Malignant Neoplasm
DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.
This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in…
- Conditions
- Haematological Malignancy, Malignant Neoplasm, Lymphoproliferative Disorders, Neoplasms by Histologic Type
- Trial name
- DETERMINE (NCT07440290)
- Testing
- Dabrafenib, Trametinib
- Where
- 27 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Cancer Research UK
Elevated LDL-C and High Cholesterol
A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C)
STX-1150 is an investigational therapy designed to lower LDL-C by silencing a gene called PCSK9 in the liver. STX-1150 does not edit or permanently change the gene.
- Trial name
- STX-1150-01 (NCT07428473)
- Testing
- STX-1150
- Where
- 3 sites in Australia, New Zealand
- Volunteers
- 64 people
- Sponsor
- Monash University
Discordant Cancers
Genomic Analysis of Families With a History of Discordant Cancers
The purpose of this study is to identify novel gene mutations which have contributed to significant personal and family history of cancer. Adults with and without cancer will be accrued to the study.
- Trial name
- NCT04860453
- Testing
- WES via Illumina NextSeq 550 sequencing system, Blood Draw, Skin biopsy
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Case Comprehensive Cancer Center
Celiac Disease
Celiac Disease Genomic Environmental Microbiome and Metabolomic Study
Celiac disease (CD) is a complex disease caused by eating gluten, a protein contained in wheat, rye, and barley. It is well known that many factors contribute to the development of CD, including the genes that you have and the…
- Trial name
- CDGEMM (NCT02061306)
- Where
- 2 sites in United States, Italy
- Volunteers
- 500 people
- Sponsor
- Massachusetts General Hospital
Couples Eligible for Prenatal Exome Sequencing
Parallel Sequencing of Fetal Genome and RNA in the Presence of Ultrasound Warning Signs: a Complementary Approach for the Prenatal Diagnosis of Rare Diseases.
Prenatal exome sequencing (ES) is increasingly used for fetuses with ultrasound-detected anomalies but yields 10-15% variants of uncertain significance (VUS), limiting diagnostic performance, particularly in prenatal settings…
- Trial name
- PrenOmics (NCT07790536)
- Testing
- Genome Sequencing (GS) + RNA-Sequencing (RNA-Seq)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Obesity
GWAS in a Small Group of Metabolically Healthy Obese White Adults
This is a GWAS pilot study that aims to identified possible candidate genes associate to obesity by exploring single nucleotide polymorphism (SNP) in a small group of obese , metabolically healthy white adults, matched with lean…
- Trial name
- NCT02105909
- Testing
- GWAS
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- University of Nevada, Las Vegas
Acute Myeloid Leukemia
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
The investigators will prospectively determine whether the relapse-free and overall survival in patients who have cleared their leukemia-associated mutations treated with standard consolidation chemotherapy is superior to what is…
- Trial name
- NCT02756962
- Testing
- Cytarabine, Allogeneic stem cell transplant, Bone marrow aspiration
- Where
- 3 sites in United States
- Volunteers
- 107 people
- Sponsor
- Washington University School of Medicine
Multiple Sclerosis
Study of myMS in Participants With a Diagnosis of Multiple Sclerosis
This is a pilot study looking at the feasibility of a mobile application (app) to collect data from active tasks (questionnaires, 6Mapp™, COGapp™, VISapp™), clinical magnetic resonance imaging information and conduct genome-wide…
- Trial name
- NCT03111394
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- University of Southern California
Appendiceal Cancer
Molecular Characterisation of Appendiceal Cancer
Patients ≥ 18 years old who have been diagnosed with appendiceal cancer with peritoneal metastases, have had cytoreductive surgery, have availability of archival tumour tissue and have consented to our institutional biobank…
- Trial name
- NCT05364788
- Testing
- Retrospective tissue sample analysis
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- The Christie NHS Foundation Trust
Genetic Screening, Adolescent
Engaging Adolescents in Decisions About Return of Genomic Research Results
Recent recommendations to return children's results for adult-onset conditions to parents anytime whole exome or genome sequencing is performed, as well as growing expectations to return research results to participants on a…
- Conditions
- Genetic Screening, Adolescent, Genetic Change, Shared Decision Making
- Trial name
- NCT04481061
- Testing
- Electronic Decision Tool
- Where
- 2 sites in United States
- Volunteers
- 787 people, healthy volunteers welcome
- Sponsor
- Children's Hospital Medical Center, Cincinnati
Sarcoidosis
Genomic Research in Sarcoidosis
This project is designed to address the following hypothesis: Distinct patterns in lung microbiome are characteristic of sarcoidosis phenotypes and reflected in changes in systemic inflammatory responses as measured by peripheral…
- Trial name
- GRADS Sarc (NCT01831739)
- Where
- 9 sites in United States
- Volunteers
- 368 people
- Sponsor
- University of Pittsburgh
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.